What is the 13F Pro Quality Score for RVMD?

13F Pro ranks Revolution Medicines, Inc. (RVMD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RVMD's current score at https://13fpro.ai/research/RVMD (free sign-up required for the full ranking).

Where does 13F Pro source RVMD data?

All Revolution Medicines, Inc. fundamentals and ownership data come directly from SEC EDGAR. Revolution Medicines, Inc. files with the SEC under CIK 1628171. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RVMD in?

Revolution Medicines, Inc. (RVMD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RVMD research updated on 13F Pro?

RVMD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Revolution Medicines, Inc.(RVMD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1628171 RVMD stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

RVMD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Revolution Medicines, Inc. (RVMD), a Healthcare sector company. RVMD is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Revolution Medicines, Inc. reports net income of $-453.8M, free cash flow of $-355.7M. Top institutional holders of RVMD by reported 13-F value include FARALLON CAPITAL MANAGEMENT, BlackRock,, JANUS HENDERSON GROUP PLC, based on the most recent SEC filings. RVMD trades on the Nasdaq exchange and files with the SEC under CIK 1628171. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RVMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Revolution Medicines, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-453.8M

Free Cash Flow

Q1 2026

$-355.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-100.0% YoY

$0.00FY 2024

FY19 $50.0MFY21 $29.4MFY23 $11.6MFY24 $0.00

Net Income

-37.5% YoY

$-600.0MFY 2024

FY19 $-47.7MFY21 $-187.0MFY23 $-436.4MFY24 $-600.0M

Operating Income

-41.5% YoY

$-689.5MFY 2024

FY19 $-54.1MFY21 $-188.0MFY23 $-487.2MFY24 $-689.5M

EPS (Diluted)

+7.3% YoY

$-3.58FY 2024

FY19 —FY21 $-2.57FY23 $-3.86FY24 $-3.58

Total Assets

+24.1% YoY

$2.56BFY 2024

FY19 $220.5MFY21 $738.0MFY23 $2.06BFY24 $2.56B

Op. Cash Flow

-59.0% YoY

$-557.4MFY 2024

FY19 $-49.6MFY21 $-147.2MFY23 $-350.6MFY24 $-557.4M

Metric	FY 2024	FY 2023	FY 2021	FY 2019	FY 2018	FY 2017
Revenue	$0.00 -100.0%	$11.6M -60.6%	$29.4M -41.3%	$50.0M +148.2%	$20.2M	—
Net Income	$-600.0M -37.5%	$-436.4M -133.4%	$-187.0M -292.3%	$-47.7M -14.1%	$-41.8M	—
Operating Income	$-689.5M -41.5%	$-487.2M -159.1%	$-188.0M -247.4%	$-54.1M -34.2%	$-40.3M	—
EPS (Diluted)	$-3.58 +7.3%	$-3.86 -50.2%	$-2.57	—	—	—
Total Assets	$2.56B +24.1%	$2.06B +179.4%	$738.0M +234.6%	$220.5M	—	—
Operating Cash Flow	$-557.4M -59.0%	$-350.6M -138.2%	$-147.2M -196.6%	$-49.6M -4190.4%	$1.2M	—

AI Insight: RVMD Financial Trends

RVMD's quarterly cash burn accelerated dramatically from $128M in Q2 2024 to $354M in Q1 2026, while equity declined from $2,265M to $1,500M.

• Operating cash flow burn worsened from $128M in Q2 2024 to $354M in Q1 2026.

• Net losses deepened from $133M in Q2 2024 to $454M in Q1 2026.

• Equity declined from peak of $2,265M in Q4 2024 to $1,500M in Q1 2026.

⚠ Cash burn rate doubled year-over-year from $194M in Q1 2025 to $354M in Q1 2026.

⚠ Company burning through equity base with no revenue generation visible across eight quarters.

AI Insight: RVMD Ratio Trends

Return metrics deteriorated sharply with ROE falling from -32.9% in Q2 2024 to -121.0% in Q1 2026.

• ROE declined consistently from -32.9% in Q2 2024 to -121.0% in Q1 2026.

• ROA weakened from -29.5% in Q2 2024 to -80.5% in Q1 2026.

• ROIC dropped from -38.7% in Q2 2024 to -79.0% in Q3 2025 before data gap.

⚠ Accelerating deterioration in Q4 2025 and Q1 2026 with ROE falling 32pp over two quarters.

⚠ Missing ROIC data in Q1 2026 limits visibility into capital efficiency trends.

Get alerted when RVMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Revolution Medicines, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RVMD

FARALLON CAPITAL MANAGEMENT LLC
$1.3B13,604,796 sh
BlackRock, Inc.
$1.1B11,212,706 sh
JANUS HENDERSON GROUP PLC
$949.5M9,766,496 sh
BAKER BROS. ADVISORS LP
$929.3M9,555,357 sh
FMR LLC
$823.2M8,464,314 sh
VANGUARD CAPITAL MANAGEMENT LLC
$813.2M8,362,284 sh
Nextech Invest, Ltd.
$739.2M7,601,087 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$729.6M7,502,623 sh
Paradigm Biocapital Advisors LP
$647.3M6,655,703 sh
WELLINGTON MANAGEMENT GROUP LLP
$586.2M6,027,819 sh

Fund	Value	Shares
FARALLON CAPITAL MANAGEMENT LLC	$1.3B	13,604,796
BlackRock, Inc.	$1.1B	11,212,706
JANUS HENDERSON GROUP PLC	$949.5M	9,766,496
BAKER BROS. ADVISORS LP	$929.3M	9,555,357
FMR LLC	$823.2M	8,464,314
VANGUARD CAPITAL MANAGEMENT LLC	$813.2M	8,362,284
Nextech Invest, Ltd.	$739.2M	7,601,087
VANGUARD PORTFOLIO MANAGEMENT LLC	$729.6M	7,502,623
Paradigm Biocapital Advisors LP	$647.3M	6,655,703
WELLINGTON MANAGEMENT GROUP LLP	$586.2M	6,027,819

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RVMD on your watchlist

Track score changes the day Revolution Medicines, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RVMD a good stock to buy?

13F Pro's AI-powered analysis of Revolution Medicines, Inc. (RVMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RVMD are available on the RVMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RVMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RVMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Revolution Medicines, Inc.'s investment landscape.